{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T10:58:00Z","timestamp":1740135480827,"version":"3.37.3"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences","award":["No. 2021-I2M-1-009"],"award-info":[{"award-number":["No. 2021-I2M-1-009"]}]},{"name":"China FH Registration Research","award":["2019-ZX15"],"award-info":[{"award-number":["2019-ZX15"]}]},{"name":"Capital\u2019s  Funds for Health Improvement and Research","award":["2022-2-4172"],"award-info":[{"award-number":["2022-2-4172"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Familial hypercholesterolemia (FH) leads to high plasma low-density lipoprotein cholesterol (LDL-C) levels and early cardiovascular morbidity and mortality. We treated a pair of siblings with FH. The cardiovascular manifestations in the proband were more severe than those in his elder sister, although they had almost similar LDL-C levels, ages, and lifestyles. Herein, we report the cases of this family to explore the possible causes of clinical phenotypic differences within the same genetic background.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>We treated a 27-year-old male patient and his 30-year-old sister, both with FH. The coronary angiogram in the male patient revealed 80, 70, and 100% stenosis of the initial, distal right coronary artery branch, and left anterior descending branch, respectively, whereas his sister had almost no coronary stenosis. We treated them accordingly and performed family screening. We found that the LDL-C\/particle discordance of the proband is much greater than that of his elder sister. In addition, the average size of LDL-C particle in the proband was smaller than that in his sister.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Patients with FH have a much higher risk of premature atherosclerotic cardiovascular disease, but the clinical manifestations are heterogeneous. The smaller LDL particle size may be the underlying cause for different clinical outcomes in this pair of FH cases and be a potential novel indicator for predicting the prognosis of FH.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12872-023-03237-4","type":"journal-article","created":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T10:01:32Z","timestamp":1682935292000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Different clinical phenotypes of a pair of siblings with familial hypercholesterolemia: a case report and literature review"],"prefix":"10.1186","volume":"23","author":[{"given":"Ze-Ping","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya-Jie","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Long-Tao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7159-0189","authenticated-orcid":false,"given":"Yuan-Lin","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-Jun","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ke-Ji","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,5,1]]},"reference":[{"issue":"10","key":"3237_CR1","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1001\/jama.2015.1206","volume":"313","author":"J Besseling","year":"2015","unstructured":"Besseling J, Kastelein JJ, Defesche JC, et al. Association between familial hypercholesterolemia and prevalence of type 2 diabetes mellitus. JAMA. 2015;313(10):1029\u201336.","journal-title":"JAMA"},{"key":"3237_CR2","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.atherosclerosis.2018.06.855","volume":"277","author":"AJ Vallejo-Vaz","year":"2018","unstructured":"Vallejo-Vaz AJ, Ray KK. Epidemiology of familial hypercholesterolaemia: community and clinical. Atherosclerosis. 2018;277:289\u201397.","journal-title":"Atherosclerosis"},{"issue":"45","key":"3237_CR3","doi-asserted-by":"publisher","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","volume":"34","author":"BG Nordestgaard","year":"2013","unstructured":"Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013;34(45):3478\u201390.","journal-title":"Eur Heart J"},{"key":"3237_CR4","doi-asserted-by":"crossref","unstructured":"Task Force Members; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies. 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Atherosclerosis. 2019;290:140\u2013205.","DOI":"10.1016\/j.atherosclerosis.2019.08.014"},{"issue":"1","key":"3237_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jjcc.2017.07.002","volume":"71","author":"M Ogura","year":"2018","unstructured":"Ogura M. PCSK9 inhibition in the management of familial hypercholesterolemia. J Cardiol. 2018;71(1):1\u20137.","journal-title":"J Cardiol"},{"issue":"8","key":"3237_CR6","doi-asserted-by":"publisher","first-page":"679","DOI":"10.5551\/jat.RV17033","volume":"26","author":"H Makino","year":"2019","unstructured":"Makino H, Koezuka R, Tamanaha T, et al. Familial hypercholesterolemia and lipoprotein apheresis. J Atheroscler Thromb. 2019;26(8):679\u201387.","journal-title":"J Atheroscler Thromb"},{"issue":"10","key":"3237_CR7","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/S2213-8587(16)30041-9","volume":"4","author":"RD Santos","year":"2016","unstructured":"Santos RD, Gidding SS, Hegele RA, et al. Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel. Lancet Diabetes Endocrinol. 2016;4(10):850\u201361.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"24","key":"3237_CR8","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1093\/eurheartj\/ehz962","volume":"41","author":"J Boren","year":"2020","unstructured":"Boren J, Chapman MJ, Krauss RM, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2020;41(24):2313\u201330.","journal-title":"Eur Heart J"},{"issue":"3","key":"3237_CR9","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1080\/14656566.2019.1702970","volume":"21","author":"A Pasta","year":"2020","unstructured":"Pasta A, Cremonini AL, Pisciotta L, et al. PCSK9 inhibitors for treating hypercholesterolemia. Expert Opin Pharmacother. 2020;21(3):353\u201363.","journal-title":"Expert Opin Pharmacother"},{"issue":"6","key":"3237_CR10","doi-asserted-by":"publisher","first-page":"e3176","DOI":"10.1002\/jgm.3176","volume":"22","author":"NA Shaik","year":"2020","unstructured":"Shaik NA, Al-Qahtani F, Nasser K, et al. Molecular insights into the coding region mutations of low-density lipoprotein receptor adaptor protein 1 (LDLRAP1) linked to familial hypercholesterolemia. J Gene Med. 2020;22(6):e3176.","journal-title":"J Gene Med"},{"issue":"1","key":"3237_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1399-0004.2007.00915.x","volume":"73","author":"M Varret","year":"2008","unstructured":"Varret M, Abifadel M, Rabes JP, et al. Genetic heterogeneity of autosomal dominant hypercholesterolemia. Clin Genet. 2008;73(1):1\u201313.","journal-title":"Clin Genet"},{"issue":"2","key":"3237_CR12","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1007\/s11883-014-0482-5","volume":"17","author":"S Singh","year":"2015","unstructured":"Singh S, Bittner V. Familial hypercholesterolemia\u2013epidemiology, diagnosis, and screening. Curr Atheroscler Rep. 2015;17(2):482.","journal-title":"Curr Atheroscler Rep"},{"issue":"2","key":"3237_CR13","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/ng1161","volume":"34","author":"M Abifadel","year":"2003","unstructured":"Abifadel M, Varret M, Rabes JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003;34(2):154\u20136.","journal-title":"Nat Genet"},{"issue":"6","key":"3237_CR14","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1161\/CIRCGENETICS.115.001129","volume":"8","author":"PN Hopkins","year":"2015","unstructured":"Hopkins PN, Defesche J, Fouchier SW, et al. Characterization of autosomal dominant hypercholesterolemia caused by PCSK9 gain of function mutations and its specific treatment with alirocumab, a PCSK9 monoclonal antibody. Circ Cardiovasc Genet. 2015;8(6):823\u201331.","journal-title":"Circ Cardiovasc Genet"},{"issue":"3","key":"3237_CR15","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.jacc.2017.11.028","volume":"71","author":"L D\u2019Erasmo","year":"2018","unstructured":"D\u2019Erasmo L, Minicocci I, Nicolucci A, et al. Autosomal recessive hypercholesterolemia: long-term cardiovascular outcomes. J Am Coll Cardiol. 2018;71(3):279\u201388.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"3237_CR16","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1097\/MOL.0000000000000664","volume":"31","author":"L D\u2019Erasmo","year":"2020","unstructured":"D\u2019Erasmo L, Di Costanzo A, Arca M. Autosomal recessive hypercholesterolemia: update for 2020. Curr Opin Lipidol. 2020;31(2):56\u201361.","journal-title":"Curr Opin Lipidol"},{"issue":"18","key":"3237_CR17","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1093\/eurheartj\/ehs038","volume":"33","author":"R Huijgen","year":"2012","unstructured":"Huijgen R, Kindt I, Defesche JC, et al. Cardiovascular risk in relation to functionality of sequence variants in the gene coding for the low-density lipoprotein receptor: a study among 29,365 individuals tested for 64 specific low-density lipoprotein-receptor sequence variants. Eur Heart J. 2012;33(18):2325\u201330.","journal-title":"Eur Heart J"},{"issue":"1","key":"3237_CR18","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s12944-017-0488-4","volume":"16","author":"CS Paththinige","year":"2017","unstructured":"Paththinige CS, Sirisena ND, Dissanayake V. Genetic determinants of inherited susceptibility to hypercholesterolemia - a comprehensive literature review. Lipids Health Dis. 2017;16(1):103.","journal-title":"Lipids Health Dis"},{"issue":"9","key":"3237_CR19","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1161\/ATVBAHA.116.307514","volume":"36","author":"DIL Perez","year":"2016","unstructured":"Perez DIL, Alonso R, Mata N, et al. Coronary heart disease, peripheral arterial disease, and stroke in familial hypercholesterolaemia: insights from the SAFEHEART Registry (Spanish Familial Hypercholesterolaemia Cohort Study). Arterioscler Thromb Vasc Biol. 2016;36(9):2004\u201310.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"8","key":"3237_CR20","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/ncpcardio0941","volume":"4","author":"GF Watts","year":"2007","unstructured":"Watts GF, Lewis B, Sullivan DR. Familial hypercholesterolemia: a missed opportunity in preventive medicine. Nat Clin Pract Cardiovasc Med. 2007;4(8):404\u20135.","journal-title":"Nat Clin Pract Cardiovasc Med"},{"issue":"22","key":"3237_CR21","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1016\/j.jacc.2016.03.520","volume":"67","author":"AV Khera","year":"2016","unstructured":"Khera AV, Won HH, Peloso GM, et al. Diagnostic yield and clinical utility of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia. J Am Coll Cardiol. 2016;67(22):2578\u201389.","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"3237_CR22","doi-asserted-by":"publisher","first-page":"3956","DOI":"10.1210\/jc.2012-1563","volume":"97","author":"M Benn","year":"2012","unstructured":"Benn M, Watts GF, Tybjaerg-Hansen A, et al. Familial hypercholesterolemia in the danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication. J Clin Endocrinol Metab. 2012;97(11):3956\u201364.","journal-title":"J Clin Endocrinol Metab"},{"key":"3237_CR23","doi-asserted-by":"crossref","unstructured":"Scientific Steering Committee on behalf of the Simon Broome Register Group. Risk of fatal coronary heart disease in familial hypercholesterolaemia. BMJ. 1991;303(6807):893\u20136.","DOI":"10.1136\/bmj.303.6807.893"},{"issue":"2","key":"3237_CR24","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1097\/00041433-200204000-00008","volume":"13","author":"AC Jansen","year":"2002","unstructured":"Jansen AC, van Wissen S, Defesche JC, et al. Phenotypic variability in familial hypercholesterolaemia: an update. Curr Opin Lipidol. 2002;13(2):165\u201371.","journal-title":"Curr Opin Lipidol"},{"issue":"7","key":"3237_CR25","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.numecd.2010.10.011","volume":"22","author":"E Jarauta","year":"2012","unstructured":"Jarauta E, Mateo-Gallego R, Gilabert R, et al. Carotid atherosclerosis and lipoprotein particle subclasses in familial hypercholesterolaemia and familial combined hyperlipidaemia. Nutr Metab Cardiovasc Dis. 2012;22(7):591\u20137.","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"2","key":"3237_CR26","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1097\/MOL.0000000000000391","volume":"28","author":"RD Santos","year":"2017","unstructured":"Santos RD. Phenotype vs. genotype in severe familial hypercholesterolemia: what matters most for the clinician? Curr Opin Lipidol. 2017;28(2):130\u20135.","journal-title":"Curr Opin Lipidol"},{"issue":"6","key":"3237_CR27","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1111\/j.1365-2796.2004.01405.x","volume":"256","author":"AC Jansen","year":"2004","unstructured":"Jansen AC, van Aalst-Cohen ES, Tanck MW, et al. The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients. J Intern Med. 2004;256(6):482\u201390.","journal-title":"J Intern Med"},{"issue":"22","key":"3237_CR28","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1161\/CIRCULATIONAHA.116.024541","volume":"135","author":"DIL Perez","year":"2017","unstructured":"Perez DIL, Alonso R, Mata N, et al. Predicting cardiovascular events in familial hypercholesterolemia: the SAFEHEART Registry (Spanish Familial Hypercholesterolemia Cohort Study). Circulation. 2017;135(22):2133\u201344.","journal-title":"Circulation"},{"issue":"1","key":"3237_CR29","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.gheart.2013.01.001","volume":"8","author":"RS D\u2019Agostino","year":"2013","unstructured":"D\u2019Agostino RS, Pencina MJ, Massaro JM, et al. Cardiovascular disease risk assessment: insights from Framingham. Glob Heart. 2013;8(1):11\u201323.","journal-title":"Glob Heart"},{"issue":"6","key":"3237_CR30","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.107.699579","volume":"117","author":"RS D\u2019Agostino","year":"2008","unstructured":"D\u2019Agostino RS, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117(6):743\u201353.","journal-title":"Circulation"},{"issue":"1","key":"3237_CR31","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/joim.12981","volume":"287","author":"A Vuorio","year":"2020","unstructured":"Vuorio A, Watts GF, Schneider WJ, et al. Familial hypercholesterolemia and elevated lipoprotein(a): double heritable risk and new therapeutic opportunities. J Intern Med. 2020;287(1):2\u201318.","journal-title":"J Intern Med"},{"issue":"6","key":"3237_CR32","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.jacl.2007.10.001","volume":"1","author":"WC Cromwell","year":"2007","unstructured":"Cromwell WC, Otvos JD, Keyes MJ, et al. LDL particle number and risk of future cardiovascular disease in the Framingham Offspring Study - implications for LDL management. J Clin Lipidol. 2007;1(6):583\u201392.","journal-title":"J Clin Lipidol"},{"issue":"2","key":"3237_CR33","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jacl.2011.02.001","volume":"5","author":"JD Otvos","year":"2011","unstructured":"Otvos JD, Mora S, Shalaurova I, et al. Clinical implications of discordance between low-density lipoprotein cholesterol and particle number. J Clin Lipidol. 2011;5(2):105\u201313.","journal-title":"J Clin Lipidol"},{"issue":"16","key":"3237_CR34","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1016\/j.jacc.2013.07.056","volume":"62","author":"D Urban","year":"2013","unstructured":"Urban D, Poss J, Bohm M, et al. Targeting the proprotein convertase subtilisin\/kexin type 9 for the treatment of dyslipidemia and atherosclerosis. J Am Coll Cardiol. 2013;62(16):1401\u20138.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"3237_CR35","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1097\/MOL.0000000000000601","volume":"30","author":"S Spolitu","year":"2019","unstructured":"Spolitu S, Dai W, Zadroga JA, et al. Proprotein convertase subtilisin\/kexin type 9 and lipid metabolism. Curr Opin Lipidol. 2019;30(3):186\u201391.","journal-title":"Curr Opin Lipidol"},{"issue":"10","key":"3237_CR36","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1016\/j.amjcard.2017.02.020","volume":"119","author":"A Baruch","year":"2017","unstructured":"Baruch A, Mosesova S, Davis JD, et al. Effects of RG7652, a monoclonal antibody against PCSK9, on LDL-C, LDL-C subfractions, and inflammatory biomarkers in patients at high risk of or with established coronary heart disease (from the phase 2 EQUATOR study). Am J Cardiol. 2017;119(10):1576\u201383.","journal-title":"Am J Cardiol"},{"issue":"11","key":"3237_CR37","doi-asserted-by":"publisher","first-page":"e002224","DOI":"10.1161\/JAHA.115.002224","volume":"4","author":"MJ Koren","year":"2015","unstructured":"Koren MJ, Kereiakes D, Pourfarzib R, et al. Effect of PCSK9 inhibition by alirocumab on lipoprotein particle concentrations determined by nuclear magnetic resonance spectroscopy. J Am Heart Assoc. 2015;4(11):e002224.","journal-title":"J Am Heart Assoc"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-023-03237-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-023-03237-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-023-03237-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T10:03:36Z","timestamp":1682935416000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-023-03237-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,1]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3237"],"URL":"https:\/\/doi.org\/10.1186\/s12872-023-03237-4","relation":{},"ISSN":["1471-2261"],"issn-type":[{"type":"electronic","value":"1471-2261"}],"subject":[],"published":{"date-parts":[[2023,5,1]]},"assertion":[{"value":"29 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the ethics committee of Fuwai Hospital, Chinese Academy of Medical Sciences (2020\u20131335), and the subjects have signed the informed consent form.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Patient\u2019s data are anonymized, and we have obtained written informed consent from the patient for the publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no competing interests to declare regarding this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"227"}}